<DOC>
	<DOC>NCT01707745</DOC>
	<brief_summary>Prospective study to evaluate the efficacy and safety of intravitreal bevacizumab In retinopathy of prematurity (ROP). Bevacizumab 0.75 mg in 0.03 ml was given to stage 2+ or stage 3+ ROP in Zone I or Zone II.</brief_summary>
	<brief_title>Efficacy and Safety of Intravitreal Bevacizumab for Threshold ROP.</brief_title>
	<detailed_description />
	<mesh_term>Retinopathy of Prematurity</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>stage 2+ or stage 3+ Retinopathy of prematurity in Zone I or Zone II. Informed written consent by parents or guardian. Refusal to give consent Critically ill neonates.</criteria>
	<gender>All</gender>
	<minimum_age>32 Weeks</minimum_age>
	<maximum_age>42 Weeks</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>